Genmab — Oktober 2019
-
and i guess this is the article the Dutch financial newspaper really interviewed Jan for (in dutch again) https://fd.nl/ondernemen/1318527/terug-aan-de-top-na-tegenvaller-met-kankermedicijn?utm_medium=social&utm_source=twitter&utm_campaign=SHR_ARTT_20191008&utm_content=ondernemen#
-
Så røg 1.350.
-
Ser dog ikke specielt overbevisende ud.
-
Gode tal i morgen vil nok kunne ses på omsætning sidst på dagen ,, Nogen kender jo tallene.....
-
jnj tal
-
Så undskyld , jeg er Åbenbart en uge foran i mit hovede , var sikker på at det var denne onsdag... så må jeg hellere vente en uge mere
-
Lazertinib in patients with..... non-small-cell lung cancer... https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30504-2/fulltext
-
nohope..Vi kan tage den over mail. [email protected]
-
DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma - https://www.nature.com/articles/s41375-019-0587-5
-
Hvor læser du det henne Pensionist?
another study to upregulate/enhance CD38 expression, like we saw with ATRA and Panobinostat. daratumumab targets CD38, but during treatment there is loss of CD38 expression on the MM cells.Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind